The role of monoamine oxidase inhibitors in current psychiatric practice

Journal of Psychiatric Practice

Volumn 10, Issue 4, 2004, Pages 239-248

  Fiedorowicz, Jess G ^a,b   Swartz, Karen L ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Atypical depression; Bipolar depression; Dosage; Drug response; Isocarboxazid; Major depression; Moclobemide; Monoamine oxidase inhibitors (MAOIs); Phenelzine; Physician prescribing practices; Psychopharmacology; Selegiline; Tranylcypromine

Indexed keywords

AMPHETAMINE; CIMETIDINE; COCAINE; EPHEDRINE; FLUPHENAZINE; IPRONIAZID; ISOCARBOXAZID; LINEZOLID; MOCLOBEMIDE; MONOAMINE OXIDASE INHIBITOR; OMEPRAZOLE; PETHIDINE; PHENELZINE; PHENYLEPHRINE; PSEUDOEPHEDRINE; PYRIDOXINE; SEROTONIN AGONIST; TRANYLCYPROMINE; TRYPTOPHAN;

AUTONOMIC HYPERREFLEXIA; BIPOLAR DEPRESSION; CLINICAL PRACTICE; CLINICAL RESEARCH; DIAPHORESIS; DIET; DIZZINESS; DROWSINESS; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG RESEARCH; EDEMA; FOOD DRUG INTERACTION; HUMAN; HYPERREFLEXIA; HYPERTENSIVE CRISIS; INSOMNIA; LIVER TOXICITY; MAJOR DEPRESSION; MENTAL HEALTH; MYALGIA; MYOCLONUS; NAUSEA; ORTHOSTATIC HYPOTENSION; PARESTHESIA; PRESCRIPTION; PSYCHIATRIST; PSYCHOPHARMACOTHERAPY; RESTLESSNESS; REVIEW; SEDATION; SEROTONIN SYNDROME; SEXUAL DYSFUNCTION; SIDE EFFECT; SYMPTOM; TABLET FORMULATION; TREATMENT INDICATION; WEIGHT GAIN;

DEPRESSIVE DISORDER; DRUG INTERACTIONS; HUMANS; MONOAMINE OXIDASE INHIBITORS; PHYSICIAN'S PRACTICE PATTERNS; TREATMENT OUTCOME;

EID: 3342958920     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200407000-00005     Document Type: Review

References (120)

1. Kennedy SH. Continuation and maintenance treatments in major depression: The neglected role of monoamine oxidase inhibitors. J Psychiatry Neurosci 1997;22:127-31.
2. Fava M. New approaches to the treatment of refractory depression. J Clin Psychiatry 2000;61:26-32.
3. Nutt D, Glue P. Monoamine oxidase inhibitors: Rehabilitation from recent research? Br J Psychiatry 1989;154:287-91.
4. Petersen T, Dording C, Neault NB, et al. A survey of prescribing practices in the treatment of depression. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:177-87.
5. Olfson M, Klerman GL. Trends in the prescription of antidepressants by office-based psychiatrists. Am J Psychiatry 1993;150:571-7.
6. Olfson M, Marcus SC, Pincus HA, et al. Antidepressant prescribing practices of outpatient psychiatrists. Arch Gen Psychiatry 1998;55:310-6.
7. Pare CMB. The present status of monoamine oxidase inhibitors. Br J Psychiatry 1985;146:576-84.
8. Medical Research Council. Clinical trial of the treatment of depressive illness. Br J Psychiatry 1965;1:881-6.
9. Robinson DS, Nies A, Ravaris L, et al. Clinical pharmacology of phenelzine. Arch Gen Psychiatry 1978;35:629-35.
10. Balon R, Mufti R, Arfken CL. A survey of prescribing practices for monoamine oxidase inhibitors. Psychiatr Serv 1999;50:945-7.
11. Clary C, Mandos LA, Schweizer E. Results of a brief survey of the prescribing practices for monoamine oxidase inhibitor antidepressants. J Clin Psychiatry 1990;51:226-31.
12. Fava M. Management of nonresponse and intolerance: Switching strategies. J Clin Psychiatry 2000;61:10-2.
13. Cooper AJ. Tyramine and irreversible monoamine oxidase inhibitors in clinical practice. Br J Psychiatry 1989;155:38-45.
14. Nierenberg AA. Treatment choice after one antidepressant fails: A survey of northeastern psychiatrists. J Clin Psychiatry 2003;52:383-5.
15. Zarate CA, Tohen M, Baraibar G, et al. Prescribing trends in antidepressants in bipolar depression. J Clin Psychiatry 1995;56:260-4.
16. Himmelhoch JM, Thase ME, Mallinger AG, et al. Tranylcypromine versus imipramine in anergic bipolar depression. Am J Psychiatry 1991;148:910-6.
17. Thase ME, Trivedi MH, Rush AJ. MAOIs in the contemporary treatment of depression. Neuropsychopharmacology 1995;12:185-219.
18. Kukopulos A, Caliari B, Tundo A, et al. Rapid cyclers, temperament, and antidepressants. Compr Psychiatry 1983;24:249-58.
19. Amsterdam JD, Hornig-Rohan M. Treatment algorithms in treatment-resistant depression. Psychiatr Clin North Am 1996;19:371-85.
20. Keller MB, Klerman GL, Lavori PW, et al. Treatment received by depressed patients. JAMA 1982;248:1848-55.
21. Amsterdam JD, Chopra M. Monoamine oxidase inhibitors revisited. Psychiatric Annals 2001;31:361-70.
22. Guze BH, Baxter LR, Rego J. Refractory depression treated with high doses of a monoamine oxidase inhibitor. J Clin Psychiatry 1987;48:31-2.
23. Davidson J, Miller R, Turnbill CD, et al. An evaluation of two doses of isocarboxazid in depression. J Affect Disord 1984;6:201-7.
24. Ravaris CL, Nies A, Robinson DS, et al. A multiple-dose, controlled study of phenelzine in depression-anxiety states. Arch Gen Psychiatry 1976;33:347-50.
25. Tyrer P, Gardner M, Lambourn J, et al. Clinical and pharmacokinetic factors affecting response to phenelzine. Br J Psychiatry 1980;136:359-65.
26. Crane GE. Iproniazid (Marsilid) phosphate, a therapeutic agent for mental disorders and debilitating diseases. Psychiatric Research Reports 1957;8:142-52.
27. West ED, Dally PJ. Effects of iproniazid in depressive syndromes. BMJ 1959;1:1491-4.
28. Schildkraut JJ. The catecholamines hypothesis of affective disorders: A review of current evidence. Am J Psychiatry 1964;122:509-22.
29. Dunlop E, DeFelice EA, Bergen JR, et al. The relationship between MAO inhibition and improvement of depression: Preliminary results with intravenous modaline sulfate (W3207B). Psychosomatics 1965;VI:1-7.
30. Bymaster FP, McNamara RK, Tran PV. New approaches to developing antidepressants by enhancing monoaminergic neurotransmission. Expert Opin Investig Drugs 2003;12:531-43.
31. Moreno FA, Heninger GR, McGahuey CA, et al. Tryptophan depletion and risk of depression relapse: A prospective study of tryptophan depletion as a potential predictor of depressive episodes. Biol Psychiatry 2000;48:327-9.
32. Delgado PL, Charney DS, Price LH, et al. Serotonin function and the mechanism of antidepressant action: Reversal of antidepressant-induced remission by rapid depletion of plasma tryptophan. Arch Gen Psychiatry 1990;47:411-8.
33. Livingston MG, Livingston HM. Monoamine oxidase inhibitors: An update on drug interactions. Drug Saf 1996;14:218-27.
34. Baker GB, Coutts RT, McKenna KF, et al. Insights into the mechanisms of action of the MAO inhibitors phenelzine and tranylcypromine: A review. J Psychiatr Neurosci 1992;17:206-14.
35. Mallinger AG, Smith E. Pharmacokinetics of monoamine oxidase inhibitors. Psychopharmacol Bull 1991;27:493-502.
36. Davidson J, McLeod MN, White HL, et al. Inhibition of platelet monoamine oxidase in depressed subjects treated with phenelzine. Am J Psychiatry 1978;135:470-2.
37. Breshnahan DB, Pandey GN, Janicak PG, et al. MAO inhibition and clinical response in depressed patients treated with phenelzine. J Clin Psychiatry 1990;51:47-50.
38. Raft D, Davidson J, Wasik J, et al. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline, and placebo. Neuropsychobiology 1981;7:122-6.
39. Bartholomew AA. An evaluation of tranylcypromine ("Parnate") in the treatment of depression. Med J Aust 1962;49:655-62.
40. Davidson J, Turnbill C. Isocarboxazid: Efficacy and tolerance. J Affect Disord 1983;5:183-9.
41. Escobar JI, Schiele BC, Zimmerman R. The tranylcypromine isomers: A controlled clinical trial. Am J Psychiatry 1974;131:1025-6.
42. Evans DL, Davidson J, Raft T. Early and late side-effects of phenelzine. J Clin Psychopharmacol 1982;2:208-10.
43. Fulton B, Benfield P. Moclobemide: An update of its pharmacological properties and therapeutic use. Drugs 1996;52:450-74.
44. Fava M. Weight gain and antidepressants. J Clin Psychiatry 2000;61:37-41.
45. Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors. Part I. A comparative study. J Clin Psychopharmacol 1984;4:270-8.
46. Gomez-Gil E, Salmeron JM, Mas A. Phenelzine-induced fulminant hepatic failure. Ann Intern Med 1996;124:692-3.
47. Robinson DS. Monoamine oxidase inhibitors: A new generation. Psychopharmacol Bull 2002;36:124-38.
48. Falon B, Foote B, Walsh T, et al. "Spontaneous" hypertensive episodes with monoamine oxidase inhibitors. J Clin Psychiatry 1988;49:163-5.
49. Linet LS. Mysterious MAOI hypertensive episodes. J Clin Psychiatry 1986;47:563-5.
50. Lavin MR, Mendelwitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993;34:146-51.
51. Fischer P. Serotonin syndrome in the elderly after antidepressive monotherapy. J Clin Psychopharmacol 1995;15:440-2.
52. Sternbach H. The serotonin syndrome. Am J Psychiatry 1991;148:705-13.
53. Neuvonen PJ, Pohjola-Sintonen S, Tacke U, et al. Five fatal cases of serotonin syndrome after moclobemide-citalopram or moclobemide-clomipramine overdoses. Lancet 1993;342:1419.
54. Linden CH, Rumack BH, Strehlke C. Monoamine oxidase inhibitor overdose. Ann Emerg Med 1984;13:1137-44.
55. Baker GB, Urichuk LJ, McKenna KF, et al. Metabolism of monoamine oxidase inhibitors. Cell Mol Neurobiol 1999;19:411-26.
56. Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors. Biol Pharm Bull 2003;26:386-90.
57. Marangell LB. Switching antidepressants for treatment-resistant disorder. J Clin Psychiatry 2001;62:12-7.
58. Gitlin MJ. Venlafaxine, monoamine oxidase inhibitors, and the serotonin syndrome. J Clin Psychopharmacol 1997;17:66-7.
59. Szuba MP, Hornig-Rohan M, Amsterdam JD. Rapid conversion from one monoamine oxidase inhibitor to another. J Clin Psychiatry 1997;58:307-10.
60. Bodner RA, Lynch T, Lewis L, et al. Serotonin syndrome. Neurology 1995;45:219-23.
61. Volz H-P, Gleiter CH. Monoamine oxidase inhibitors: A perspective on their use in the elderly. Drugs Aging 1998;13:341-55.
62. Noorily S, Hantler CB. Monoamine oxidase inhibitors and cardiac anesthesia revisited. South Med J 1997;90:836-8.
63. Pope HG, Jonas JM, Hudson JI, et al. Toxic reactions to the combination of monoamine oxidase inhibitors and tryptophan. Am J Psychiatry 1985;142:491-2.
64. Livingston MG. Interactions with selective MAOIs. Lancet 1995;345:533-4.
65. Hammerness P, Parada H, Abrams A. Linezolid: MAOI activity and potential drug interactions. Psychosomatics 2002;43:248-9.
66. Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: A re-examination. Can J Psychiatry 1984;29:707-11.
67. Blackwell B. Hypertensive crisis due to monoamine-oxidase inhibitors. Lancet 1963;11:849-51.
68. Blackwell B, Marley E, Price J, et al. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry 1967;113:349-65.
69. Gardner DM, Shulman KI, Walker SE, et al. The making of a user friendly MAOI diet. J Clin Psychiatry 1996;57:99-104.
70. McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry 1982;43:178-81.
71. Shulman KI, Walker SE, MacKenzie S, et al. Dietary restriction, tyramine, and the use of monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:397-402.
72. Shulman KI, Walker SE. Refining the MAOI diet: Tyramine content of pizzas and soy products. J Clin Psychiatry 1999;60:191-3.
73. Shulman KI, Tailor SAN, Walker SE, et al. Tap (draft) beer and monoamine oxidase inhibitor dietary restrictions. Can J Psychiatry 1997;42:310-2.
74. Walker SE, Shulman KI, Tailor SAN, et al. Tyramine content of previously restricted foods in monoamine oxidase inhibitor diets. J Clin Psychopharmacol 1996;16:383-8.
75. Bieck PR, Antonin KH. Oral tyramine pressor test and the safety of monoamine oxidase inhibitor drugs: Comparison of brofaromine and tranylcypromine in healthy subjects. J Clin Psychiatry 1988;8:237-45.
76. Feinberg S, Holzer B. Clarifying the safety of the MAOI diet and pizza. J Clin Psychiatry 2000;61:145.
77. Folks DG. Monoamine oxidase inhibitors: Reappraisal of dietary consideration. J Clin Psychopharmacol 1983;3:249-52.
78. Neil JF, Licata SM, May SJ, et al. Dietary noncompliance during treatment with tranylcypromine. J Clin Psychiatry 1979;40:33-7.
79. Sweet RA, Brown EJ, Heimberg RG, et al. Monoamine oxidase inhibitor dietary restrictions: What are we asking patients to give up? J Clin Psychiatry 1995;56:196-201.
80. American Psychiatric Association. Mood disorders. In: Diagnostic and statistical manual of mental disorders, fourth edition, text revision. Washington, DC: American Psychiatric Association; 2000:325-428.
81. Clayton P. Depression subtyping: Treatment implications. J Clin Psychiatry 1998;59:5-12.
82. Nierenberg AA, Alpert JE, Pava J, et al. Course and treatment of atypical depression. J Clin Psychiatry 1998;59:5-9.
83. Liebowitz MR. Depression with anxiety and atypical depression. J Clin Psychiatry 1993;52:10-4.
84. Parker G, Roy K, Mitchell P, et al. Atypical depression: A reappraisal. Am J Psychiatry 2002;159:1470-9.
85. Lam RW, Stewart JN. The validity of atypical depression in DSM-IV. Compr Psychiatry 1996;37:375-83.
86. Davidson J, Raft D, Pelton S. An outpatient evaluation of phenelzine and imipramine. J Clin Psychiatry 1987;48:143-6.
87. Davidson J, Pelton S. Forms of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986;17:87-95.
88. Liebowitz MR, Quitkin FM, Stewart JW, et al. Antidepressant specificity in atypical depression. Arch Gen Psychiatry 1988;45:129-37.
89. Liebowitz MR, Quitkin FM, Stewart JW, et al. Phenelzine v imipramine in atypical depression: A preliminary report. Arch Gen Psychiatry 1984;41:669-77.
90. McGrath PJ, Stewart JW, Nunes EV, et al. A double-blind crossover trial of imipramine and phenelzine for outpatients with treatment-refractory depression. Am J Psychiatry 1993;150:118-23.
91. Quitkin FM, Stewart JW, McGrath PJ, et al. Columbia atypical depression: A subgroup of depressives with better response to MAOI than to tricyclic antidepressants or placebo. Br J Psychiatry 1993;163:30-4.
92. Stewart JW, McGrath PJ, Quitkin FM. Do age of onset and course of illness predict different treatment outcome among DSM IV depressive disorders with atypical features? Neuropsychopharmacology 2002;26:237-45.
93. Thase ME, Carpenter L, Kupfer DJ, et al. Atypical depression: Diagnostic and pharmacologic controversies. Psychopharmacol Bull 1991;27:17-22.
94. Davidson JRT, Miller RD, Turnbill CD, et al. Atypical depression. Arch Gen Psychiatry 1982;39:527-34.
95. Paykel ES, Rowan PR, Parker RR, et al. Responses to phenelzine and amitriptyline in subtypes of outpatient depression. Arch Gen Psychiatry 1982;39:1041-9.
96. White K, Razini J, Cadow B, et al. Tranylcypromine vs nortriptyline vs placebo in depressed outpatients: A controlled trial. Psychopharmacology 1984;82:258-62.
97. Pande AC, Birkett M, Fechner-Bates S, et al. Fluoxetine versus phenelzine in atypical depression. Biol Psychiatry 1996;40:1017-20.
98. Goodwin FK, Jamison KR. Medical treatment of acute bipolar depression. In: Manic-depressive illness. New York: Oxford University Press; 1990:630-64.
99. Thase ME, Mallinger AG, McKnight D, et al. Treatment of imipramine-resistant recurrent depression, IV: A double-blind crossover study of tranylcypromine for anergic bipolar depression. Am J Psychiatry 1992;149:195-8.
100. Stoll AL, Mayer PV, Kolbrener M, et al. Antidepressant-associated mania: A controlled comparison with spontaneous mania. Am J Psychiatry 1994;151:1642-5.
101. Davidson JRT, Giller EL, Zisook S, et al. An efficacy study of isocarboxazid and placebo in depression, and its relationship to depressive nosology. Arch Gen Psychiatry 1988;45:120-7.
102. Kay DWK, Garside RF, Fahy TJ. A double-blind trial of phenelzine and amitriptyline in depressed outpatients: A possible differential effect of the drugs on symptoms. Br J Psychiatry 1973;123:63-7.
103. Reynaert C, Parent M, Mirel J, et al. Moclobemide versus fluoxetine for a major depressive episode. Psychopharmacology 1995;118:183-7.
104. Georgotas A, McCue RE, Friedman E, et al. Response rate of depressive symptoms to nortriptyline, phenelzine, and placebo. Br J Psychiatry 1987;151:102-6.
105. Georgotas A, McCue RE, Hapworth W, et al. Comparative efficacy and safety of MAOIs versus TCAs in treating depression in the elderly. Biol Psychiatry 1986;21:1155-66.
106. McGrath PJ, Stewart JW, Harrison W, et al. Treatment of tricyclic refractory depression with a monoamine oxidase inhibitor antidepressant. Psychopharmacol Bull 1987;23:169-72.
107. Himmelhoch JM, Detre T, Kupfer DJ, et al. Treatment of previously intractable depressions with tranylcypromine and lithium. J Nerv Ment Dis 1972;155:216-20.
108. Thase ME, Frank E, Mallinger AG, et al. Treatment of imipramine-resistant recurrent depression, III: Efficacy of monoamine oxidase inhibitors. J Clin Psychiatry 1992;53:5-11.
109. Nolen WA, van de Putte JJ, Dijken WA, et al. Treatment strategy in depression: MAO inhibitors in depression resistant to cyclic antidepressants: Two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr 1988;78:676-83.
110. Kahn D, Silver JM, Opler LA. The safety of switching rapidly from tricyclic antidepressants to monoamine oxidase inhibitors. J Clin Psychopharmacol 1989;9:198-202.
111. Ebert D, Albert R, May A, et al. Combined SSRI-RIMA treatment in refractory depression: Safety data and efficacy. Psychopharmacology 1995;119:342-4.
112. Lotufo-Neto F, Trivedi M, Thase ME. Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression. Neuropsychopharmacology 1999;20:226-47.
113. Amsterdam JD. A double-blind, placebo-controlled trial of the safety and efficacy of selegiline transdermal system without dietary restrictions in patients with major depressive disorder. J Clin Psychiatry 2003;64:208-14.
114. Bodkin JA, Amsterdam JD. Transdermal selegiline in major depression: A double-blind, placebo-controlled, parallel group study in outpatients. Am J Psychiatry 2002;159:1869-75.
115. Sunderland T, Cohen RM, Molchan S, et al. High-dose selegiline in treatment-resistant older depressive patients. Arch Gen Psychiatry 1994;51:607-15.
116. Mann JJ, Aarons SF, Wilner PJ, et al. A controlled study of the antidepressant efficacy and side effects of (-)-deprenyl: A selective monoamine oxidase inhibitor. Arch Gen Psychiatry 1989;46:45-50.
117. McGrath PJ, Stewart JW, Harrison W, et al. A placebo-controlled trial of L-deprenyl in atypical depression. Psychopharmacol Bull 1989;25:63-7.
118. Pierre JM, Gitlin MJ. Buproprion-tranycypromine combination for treatment-refractory depression. J Clin Psychiatry 2000;61:450-1.
119. Davidson J. Adding a tricyclic antidepressant to a monoamine oxidase inhibitor. J Clin Psychopharmacol 1982;2:216.
120. Nierenberg AA, Amsterdam JD. Treatment-resistant depression: Definition and treatment approaches. J Clin Psychiatry 1990;51:39-47.